Inventiva secures a new patent in Japan, expanding the IP
protection of its lead product candidate lanifibranor
- Japanese Patent Office approved Inventiva’s patent application
relating to the use of lanifibranor for the treatment of
cirrhosis.1
- This patent strengthens Inventiva’s intellectual property with
respect to lanifibranor in Japan for the indication cirrhosis,
including cirrhosis due to MASH/NASH.
Daix (France), Long Island City (New
York, United States), July 25, 2024 – Inventiva (Euronext
Paris and Nasdaq: IVA) (“Inventiva” or the
“Company”), a clinical-stage biopharmaceutical
company focused on the development of oral small molecule therapies
for the treatment of patients with metabolic dysfunction-associated
steatohepatitis (“MASH”), also known as
non-alcoholic steatohepatitis (“NASH”), and other
diseases with significant unmet medical needs, today announced that
the Japan Patent Office (“JPO”) has approved Inventiva’s patent
application No. JP 2019-203498, protecting the use of lanifibranor
for the treatment of patients with cirrhosis. This new patent will
be valid until November 8, 2039, excluding any potential patent
term adjustments or extensions that may provide additional
protection.
The patent granted by the JPO expands the
intellectual property protection of lanifibranor for use in
patients with cirrhosis including patients with cirrhosis due to
MASH/NASH, complementing the protection previously granted by the
United States Patent and Trademark Office2. The approval
of this patent further strengthens Inventiva’s patent portfolio for
lanifibranor, the Company’s lead product candidate. To date, this
portfolio is composed of 20 patent families directly owned by
Inventiva, including 157 issued patents and more than 50 pending
patent applications. The Company’s patent portfolio, with respect
to lanifibranor, includes patents and patent applications directed
to the product lanifibranor, the methods of treatment, the
combination therapy, the processes, the formulations and diagnostic
methods.
Pierre Broqua, Ph.D., Chief Scientific
Officer and cofounder of Inventiva, stated: “We are
delighted by the Japan Patent Office's decision to grant this
patent for lanifibranor. We believe this patent not only reinforces
our intellectual property position but also highlights
lanifibranor’s potential in addressing significant unmet medical
needs in patients with cirrhosis, in particular cirrhosis due to
MASH/NASH. This new patent complements our existing patent
protection in the United States, and other regions, and strengthens
lanifibranor’s position as a leading candidate for the potential
treatment of MASH/NASH, cirrhosis and other fibrotic
diseases.”
With up to 2.7%3 of Japan's
population with MASH/NASH and no treatment approved by the Japanese
Pharmaceuticals and Medical Devices Agency (PMDA), Inventiva
believes Japan could become an important market for lanifibranor,
if approved. As previously disclosed, Inventiva entered into an
exclusive licensing agreement with Hepalys Pharma, Inc. in
September 2023 to develop and commercialize lanifibranor for the
potential treatment of MASH/NASH in Japan and South Korea.
About lanifibranor
Lanifibranor, Inventiva’s lead product
candidate, is an orally-available small molecule that acts to
induce antifibrotic, anti-inflammatory and beneficial vascular and
metabolic changes in the body by activating all three peroxisome
proliferator-activated receptor (“PPAR”) isoforms, which are
well-characterized nuclear receptor proteins that regulate gene
expression. Lanifibranor is a PPAR agonist that is designed to
target all three PPAR isoforms in a moderately potent manner, with
a well-balanced activation of PPARα and PPARδ, and a partial
activation of PPARγ. While there are other PPAR agonists that
target only one or two PPAR isoforms for activation, lanifibranor
is the only pan-PPAR agonist in clinical development for the
treatment of MASH/NASH. Inventiva believes that lanifibranor’s
moderate and balanced pan-PPAR binding profile contributes to the
favorable tolerability profile that has been observed in clinical
trials and pre-clinical studies to date. The U.S. Food and Drug
Administration has granted Breakthrough Therapy and Fast Track
designation to lanifibranor for the treatment of MASH/NASH.
About Inventiva
Inventiva is a clinical-stage biopharmaceutical
company focused on the research and development of oral small
molecule therapies for the treatment of patients with MASH/NASH and
other diseases with significant unmet medical need. The Company
benefits from a strong expertise and experience in the domain of
compounds targeting nuclear receptors, transcription factors and
epigenetic modulation. Inventiva is currently advancing one
clinical candidate, has a pipeline of two preclinical programs and
continues to explore other development opportunities to add to its
pipeline.
Inventiva’s lead product candidate,
lanifibranor, is currently in a pivotal Phase III clinical trial,
NATiV3, for the treatment of adult patients with MASH/NASH, a
common and progressive chronic liver disease.
Inventiva’s pipeline also includes odiparcil, a
drug candidate for the treatment of adult MPS VI patients. As part
of Inventiva’s decision to focus clinical efforts on the
development of lanifibranor, it suspended its clinical efforts
relating to odiparcil and is reviewing available options with
respect to its potential further development. Inventiva is also in
the process of selecting a candidate for its Hippo signaling
pathway program.
The Company has a scientific team of
approximately 90 people with deep expertise in the fields of
biology, medicinal and computational chemistry, pharmacokinetics
and pharmacology, and clinical development. It owns an extensive
library of approximately 240,000 pharmacologically relevant
molecules, approximately 60% of which are proprietary, as well as a
wholly-owned research and development facility.
Inventiva is a public company listed on
compartment B of the regulated market of Euronext Paris (ticker:
IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the
United States (ticker: IVA). www.inventivapharma.com
Contacts
Inventiva
Pascaline Clerc, PhD
EVP, Strategy and Corporate Affairs
media@inventivapharma.com
+1 202 499 8937 |
Brunswick Group
Tristan Roquet Montegon /
Aude Lepreux /
Julia Cailleteau
Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83 |
Westwicke, an ICR Company
Patricia L. Bank
Investor relations
patti.bank@westwicke.com
+1 415 513-1284 |
|
|
|
|
|
|
Important Notice
This press release contains certain
“forward-looking statements” within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
All statements, other than statements of historical facts, included
in this press release are forward-looking statements.
These statements include, but are not
limited to, forecasts and estimates with respect to Inventiva’s
intellectual property and intellectual property strategy, including
potential patent terms and related adjustments or extensions,
pre-clinical programs and clinical trials, including design,
duration, timing, recruitment costs, screening and enrollment for
those trials, including the ongoing NATiV3 Phase III clinical trial
with lanifibranor in MASH/NASH, clinical trial data releases and
publications, the information, insights and impacts that may be
gathered from clinical trials, the potential therapeutic benefits
of Inventiva’s product candidates, including lanifibranor, the
estimated market size and patient population for lanifibranor in
Japan, expectations with respect to clinical development and
commercialization of lanifibranor by Hepalys Pharma, Inc.,
including with respect to regulatory approvals, expectations with
respect to the benefits of the agreement with Hepalys Pharma, Inc.,
potential regulatory submissions, approvals and commercialization,
Inventiva’s pipeline and preclinical and clinical development
plans, the expected benefit of having received Breakthrough Therapy
Designation and Fast Track designation to lanifibranor for the
treatment of MASH/NASH, including its impact on the development and
review timeline of Inventiva’s product candidates, the potential
development of and regulatory pathway for odiparcil, and future
activities, expectations, plans, growth and prospects of Inventiva
and its partners. Certain of these statements, forecasts and
estimates can be recognized by the use of words such as, without
limitation, “believes”, “anticipates”, “expects”, “intends”,
“plans”, “seeks”, “estimates”, “may”, “will”, “would”, “could”,
“might”, “should”, “designed”, “hopefully”, “target”, “potential”,
“opportunity”, “possible”, “aim”, and “continue” and similar
expressions. Such statements are not historical facts but rather
are statements of future expectations and other forward-looking
statements that are based on management's beliefs. These statements
reflect such views and assumptions prevailing as of the date of the
statements and involve known and unknown risks and uncertainties
that could cause future results, performance, or future events to
differ materially from those expressed or implied in such
statements. Actual events are difficult to predict and may depend
upon factors that are beyond Inventiva's control. There can be no
guarantees with respect to pipeline product candidates that the
clinical trial results will be available on their anticipated
timeline, that future clinical trials will be initiated as
anticipated, that product candidates will receive the necessary
regulatory approvals, or that any of the anticipated milestones by
Inventiva or its partners will be reached on their expected
timeline, or at all. Future results may turn out to be materially
different from the anticipated future results, performance or
achievements expressed or implied by such statements, forecasts
and estimates, due to a number of factors, including
Inventiva’s prospects, including Inventiva’s ability to
continue as a going concern, whether Inventiva will be able to
raise additional funds in connection with its review of potential
financing and strategic options or otherwise, that
Inventiva cannot provide assurance on the impacts of the
Suspected Unexpected Serious Adverse Reaction
(SUSAR) on enrollment or the ultimate impact on the
results or timing of the NATiV3 trial or regulatory matters with
respect thereto, that Inventiva is a clinical-stage company with no
approved products and no historical product revenues,
Inventiva has incurred significant losses since inception,
Inventiva has a limited operating history and has never generated
any revenue from product sales, Inventiva will require additional
capital to finance its operations, in the absence of which,
Inventiva may be required to significantly curtail, delay or
discontinue one or more of its research or development programs or
be unable to expand its operations or otherwise capitalize on its
business opportunities and may be unable to continue as a going
concern, Inventiva’s ability to obtain financing and to enter into
potential transactions, Inventiva's future success is dependent on
the successful clinical development, regulatory approval and
subsequent commercialization of current and any future product
candidates, preclinical studies or earlier clinical trials are not
necessarily predictive of future results and the results of
Inventiva's and its partners’ clinical trials may not support
Inventiva's and its partners’ product candidate claims, Inventiva's
expectations with respect to its clinical trials may prove to be
wrong and regulatory authorities may require holds and/or
amendments to Inventiva’s clinical trials, Inventiva’s expectations
with respect to the clinical development plan for lanifibranor for
the treatment of MASH/NASH may not be realized and may not support
the approval of a New Drug Application, Inventiva and its partners
may encounter substantial delays beyond expectations in their
clinical trials or fail to demonstrate safety and efficacy to the
satisfaction of applicable regulatory authorities, the ability of
Inventiva and its partners to recruit and retain patients in
clinical studies, enrollment and retention of patients in clinical
trials is an expensive and time-consuming process and could be made
more difficult or rendered impossible by multiple factors outside
Inventiva's and its partners’ control, Inventiva's product
candidates may cause adverse drug reactions or have other
properties that could delay or prevent their regulatory approval,
or limit their commercial potential, Inventiva faces substantial
competition and Inventiva’s and its partners' business, and
preclinical studies and clinical development programs and
timelines, its financial condition and results of operations could
be materially and adversely affected by geopolitical events, such
as the conflict between Russia and Ukraine and related sanctions,
impacts and potential impacts on the initiation, enrollment and
completion of Inventiva’s and its partners’ clinical trials on
anticipated timelines and the state of war between Israel and Hamas
and the related risk of a larger conflict, health epidemics, and
macroeconomic conditions, including global inflation, rising
interest rates, uncertain financial markets and disruptions in
banking systems. Given these risks and uncertainties, no
representations are made as to the accuracy or fairness of such
forward-looking statements, forecasts, and estimates. Furthermore,
forward-looking statements, forecasts and estimates only speak as
of the date of this press release. Readers are cautioned not to
place undue reliance on any of these forward-looking
statements.
Please refer to the Universal Registration
Document for the year ended December 31, 2023, filed with the
Autorité des Marchés Financiers on April 3, 2024, and the Annual
Report on Form 20-F for the year ended December 31, 2023, filed
with the Securities and Exchange Commission (SEC) on April 3, 2024
for other risks and uncertainties affecting Inventiva, including
those described under the caption “Risk Factors”, and in our future
filings with the SEC. Other risks and uncertainties of which
Inventiva is not currently aware may also affect its
forward-looking statements and may cause actual results and the
timing of events to differ materially from those anticipated. All
information in this press release is as of the date of the release.
Except as required by law, Inventiva has no intention and is under
no obligation to update or review the forward-looking statements
referred to above. Consequently, Inventiva accepts no liability for
any consequences arising from the use of any of the above
statements.
1 Inventiva’s lead product candidate,
lanifibranor, is currently in a pivotal Phase III clinical trial,
NATiV3, for the treatment of adult patients with MASH/NASH, a
common and progressive chronic liver disease.
2
inventivapharma.com/wp-content/uploads/2022/11/Inventiva-PR-Lanifibranor-New-patent-US-EN-11-28-2022.pdf
3 Eguchi Y, Wong G, Lee EI, Akhtar O, Lopes R, Sumida Y.
Epidemiology of non-alcoholic fatty liver disease and non-alcoholic
steatohepatitis in Japan: A focused literature review. JGH Open.
2020 May 5;4(5):808-817.
- Inventiva - PR - Lanifibranor Cirrhosis patent Japan - 07 25
2024
Inventiva (LSE:0RNK)
過去 株価チャート
から 7 2024 まで 8 2024
Inventiva (LSE:0RNK)
過去 株価チャート
から 8 2023 まで 8 2024